Hepatitis
C Newsletter
www.HepCChallenge.org
November - December 2010
Clinical
Trials, Cohort Studies, Pilot Studies
Safety and pharmacokinetics of IDX184, a liver-targeted nucleotide
polymerase inhibitor of the hepatitis c virus, in healthy subjects. Zhou XJ, Pietropaolo
K, Chen J, Khan S, Sullivan-Bólyai J, Mayers D. Antimicrob Agents Chemother. 2010 Nov 8. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21060109
Changes
in insulin sensitivity and body weight during and after peginterferon
and ribavirin therapy for hepatitis C. Conjeevaram HS, Wahed AS, Afdhal N, et al. Gastroenterology. 2010
Nov 8. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21070775
Long-term outcome after antiviral therapy of patients with hepatitis C
virus infection and decompensated cirrhosis. Iacobellis A, Perri F, Valvano MR, Caruso N, Niro GA, Andriulli A. Clin Gastroenterol Hepatol. 2010 Nov 16. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21092761
Hepatitis C treatment among racial and ethnic groups in the IDEAL
trial. Muir AJ, Hu KQ,
Gordon SC, et al. J Viral Hepat. 2010 Nov 25. doi:
10.1111/j.1365-2893.2010.01402.x. [Epub ahead of
print]
http://www.ncbi.nlm.nih.gov/pubmed/21108699
Randomized controlled trial of pegylated interferon-alfa 2a and ribavirin in
treatment-naive chronic hepatitis C genotype 6. Lam KD, Trinh HN, Do ST, et al. Hepatology. 2010 Nov;52(5):1573-80.
http://www.ncbi.nlm.nih.gov/pubmed/21038410
Frequent multiple hepatitis C virus
infections among injection drug users in a prison setting. Pham ST, Bull RA,
Bennett JM, et al. Hepatology. 2010 Nov;52(5):1564-72.
http://www.ncbi.nlm.nih.gov/pubmed/21038409
Hepatitis C testing and treatment among
active drug users in Amsterdam: results from the DUTCH-C project. Lindenburg CE, Lambers FA, Urbanus AT, et al. Eur J Gastroenterol Hepatol. 2010 Oct 29. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21042221
Randomized trial of peginterferon alfa-2b and ribavirin
for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response. Buti M, Lurie Y, Zakharova NG, et al. Hepatology.
2010 Oct;52(4):1201-7.
http://www.ncbi.nlm.nih.gov/pubmed/20683847
Systemic vasculitis in patients with hepatitis C virus infection with
and without detectable mixed cryoglobulinemia. Terrier B, Sčne D, Dechartres A, et al. J Rheumatol. 2010 Oct 15. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20952479
Sporadic reappearance of
minute amounts of HCV RNA after successful therapy stimu-lates
cellular immune responses. Veerapu
NS, Raghuraman S, Liang TJ, Heller T, Rehermann B. Gastroenterology. 2010
Oct 29. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21040725
Cervicovaginal shedding of hepatitis C viral RNA is
associated with the presence of menstrual or other blood in cervicovaginal
fluids. Wang CC, Cook L, Tapia KA, et al. J Clin Virol. 2010 Oct 14. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20951635
Oral combination therapy with a nucleoside
polymerase inhibitor (RG7128) and danoprevir for
chronic hepatitis C genotype 1 infection (INFORM-1): A randomised,
double-blind, placebo-controlled, dose-escalation trial. Gane EJ, Roberts SK,
Stedman CA, et al. Lancet. 2010 Oct 30;376(9751):1467-75.
Epub 2010 Oct 14.
http://www.ncbi.nlm.nih.gov/pubmed/20951424
The combination of ribavirin
and peginterferon is superior to peginterferon
and placebo for children and adolescents chronic hepatitis C. Schwarz KB,
Gonzalez-Peralta RP, Murray KF, et al. . Gastroenterology. 2010 Oct 28. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21036173
Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon
alfa-2a or 2b to patients with chronic hepatitis C. Marcellin P, Forns X, Goeser T, et al. Gastro-enterology. 2010 Oct 26. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21034744
Prophylactic treatment with escitalopram of pegylated
interferon alfa-2a-induced depression in hepatitis c: a 12-week, randomized,
double-blind, placebo-controlled trial.
Diez-Quevedo C, Masnou H, Planas R, et al. J Clin Psychiatry. 2010 Oct 5. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21034680
A
multidisciplinary therapeutic approach for reducing the risk of psychiatric
side effects in patients with chronic hepatitis C treated with pegylated interferon α and ribavirin.
Neri S, Bertino G, Petralia A, et al. J Clin Gastroenterol. 2010 Oct;44(9):e210-7.
http://www.ncbi.nlm.nih.gov/pubmed/20838237
Basic
and Applied Science, Pre-Clinical Studies
Survival of hepatitis C virus in syringes:
implication for transmission among injection drug users. Paintsil E, He H, Peters C,
Lindenbach BD, Heimer R. J
Infect Dis. 2010 Oct 1;202(7):984-90.
http://www.ncbi.nlm.nih.gov/pubmed/20726768
Hepatitis C virus-specific CD8+ T cell
frequencies are associated with the responses of pegylated
interferon-α and ribavirin combination therapy
in patients with chronic hepatitis C virus infection. Tatsumi T, Takehara T, Miyagi T, et al. Hepatol
Res. 2010 Oct 7. doi:
10.1111/j.1872-034X.2010.00734.x. [Epub ahead of
print]
http://www.ncbi.nlm.nih.gov/pubmed/21040277
Early viral and peripheral blood mononuclear
cell responses to pegylated interferon and ribavirin treatment: the first 24 h. Devitt E, Lawless MW, Sadlier D, A Browne J, Walsh C, Crowe J. Eur J Gastroenterol Hepatol. 2010 Oct;22(10):1211-20.
http://www.ncbi.nlm.nih.gov/pubmed/20631625
Increased
natural killer cell cytotoxicity and NKp30 expression
protects against hepatitis C virus infection in high-risk individuals and
inhibits replication in vitro. Golden-Mason
L, Cox AL, Randall JA, Cheng L, Rosen HR. Hepatology.
2010 Nov;52(5):1581-9.
http://www.ncbi.nlm.nih.gov/pubmed/20812318
DEB025
(Alisporivir) inhibits hepatitis C virus replication
by preventing a cyclophilin a
induced cis-trans isomerisation
in domain II of NS5A. Coelmont L, Hanoulle
X, Chatterji U, et al. PLoS
One. 2010 Oct 27;5(10):e13687.
http://www.ncbi.nlm.nih.gov/pubmed/21060866
CX3CL1-CX3CR1
interaction prevents carbon tetrachloride-induced liver inflammation and
fibrosis in mice. Aoyama T, Inokuchi S, Brenner DA, Seki E. Hepatology.
2010 Oct;52(4):1390-400.
http://www.ncbi.nlm.nih.gov/pubmed/20683935
Conformational
anti-cytochrome P4502E1 (CYP2E1) auto-antibodies
contribute to necro-inflammatory injury in chronic
hepatitis C. Sutti S, Vidali M, Mombello C, Sartori M, Albano E. J Viral Hepat.
2010 Oct;17(10):685-90. doi: 10.1111/j.1365-2893.2010.01359.x.
http://www.ncbi.nlm.nih.gov/pubmed/20738774
A
new natural α-helical peptide from the venom of the scorpion Heterometrus petersii kills HCV. Yan R, Zhao Z, He Y, et al. Peptides. 2010 Oct 13. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20950663
Dynamic coinfection
with multiple viral subtypes in acute hepatitis C. Smith JA, Aberle JH, Fleming VM, et al.
http://www.ncbi.nlm.nih.gov/pubmed/21067369
HIV/HCV
Coinfection
Modeling the probability of sustained virological response to Therapy with pegylated
interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV. Medrano J, Neukam K, Rallón N, et al. Clin Infect Dis. 2010 Nov 15;51(10):1209-16.
http://www.ncbi.nlm.nih.gov/pubmed/20964522
Polymorphism in tumor necrosis factor-related
apoptosis-inducing ligand receptor 1 is associated
with poor viral response to interferon-based hepatitis C virus therapy in
HIV/hepatitis C virus-coinfected individuals. Rizza SA, Cummins NW,
Rider DN, Saeed S, Klein MB, Badley
AD. AIDS. 2010 Nov 13;24(17):2639-44.
http://www.ncbi.nlm.nih.gov/pubmed/20802294
Transient
elastography: a non-invasive tool for assessing liver
fibrosis in HIV/HCV patients. Li
Vecchi V, Soresi M, Colomba C, et al. World J Gastroenterol.
2010 Nov 7;16(41): 5225-32.
http://www.ncbi.nlm.nih.gov/pubmed/21049556
The French national prospective cohort of
patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): Early findings,
2006-2010. Loko MA, Salmon D, Carrieri
P, et al. BMC Infect Dis. 2010 Oct 22;10(1):303. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20969743
Immunological status does not influence
hepatitis C virus or liver fibrosis in HIV-Hepatitis C virus-coinfected patients. Collazos J, Cartón JA, Asensi V. AIDS Res Hum
Retroviruses. 2010 Oct 26. [Epub
ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20977357
Women experience higher rates of adverse
events during hepatitis C virus therapy in HIV infection: a meta-analysis. Bhattacharya D, Umbleja T, Carrat F, et al. J Acquir Immune Defic Syndr. 2010 Oct 1;55(2):170-5.
http://www.ncbi.nlm.nih.gov/pubmed/20622678
Evaluation of the possible influence of
hepatitis C virus and liver fibrosis on HIV type 1 immunological and virological outcomes. Collazos J, Cartón J, Asensi V. HIV Med. 2010
Oct 14. doi: 10.1111/j.1468-1293.2010.00886.x.
[Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20946441
Influence of a single nucleotide polymorphism
at the main ribavirin transporter gene on the rapid virological response to pegylated
interferon-ribavirin therapy in patients with chronic
hepatitis C virus infection. Morello J, Cuenca L,
Soriano V, et al. J Infect Dis. 2010 Oct 15;202(8):1185-91.
http://www.ncbi.nlm.nih.gov/pubmed/20812847
Prevalence and factors associated with
significant liver fibrosis assessed by transient elastometry
in HIV/hepatitis C virus-coinfected patients. Pineda JA, González J, Ortega E, et al. J Viral Hepat.
2010 Oct;17(10):714-9. doi: 10.1111/j.1365-2893.2009.01229.x.
http://www.ncbi.nlm.nih.gov/pubmed/20002560
Prediction of response to pegylated
interferon plus ribavirin by IL28B gene variation in
patients coinfected with HIV and hepatitis C virus. Pineda JA, Caruz A, Rivero A, et al. Clin Infect Dis. 2010 Oct 1;51(7):788-95.
http://www.ncbi.nlm.nih.gov/pubmed/20804372
Sustained Long-Term
Antiviral Maintenance Therapy in HCV/HIV-Coinfected
Patients (SLAM-C).
Sherman KE, Andersen JW, Butt AA, et al. J Acquir
Immune Defic Syndr. 2010
Oct 1. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20921898
An artificial neural network improves the
non-invasive diagnosis of significant fibrosis in HIV/HCV coinfected
patients. Resino S, Seoane JA, Bellón JM, et al. J Infect. 2010 Nov 10.
[Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21073895
Treatment of acute hepatitis C in human
immunodeficiency virus-infected patients: The HEPAIG study. Piroth L, Larsen C, Binquet C, et al. Hepatology.
2010 Dec;52(6):1915-21. doi: 10.1002/hep.23959. Epub
2010 Nov 9.
http://www.ncbi.nlm.nih.gov/pubmed/21064156
Complementary
and Alternative Medicine
S-adenosyl-methionine and betaine improve early virological
response in chronic hepatitis C patients with previous nonresponse.
Filipowicz M, Bernsmeier C, Terracciano L, Duong FH, Heim MH. PLoS One. 2010 Nov 8;5(11):e15492.
http://www.ncbi.nlm.nih.gov/pubmed/21079746
Silymarin use and liver disease
progression in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis
trial. Freedman ND, Curto TM, Morishima C, et al.
Aliment Pharmacol Ther. 2010 Nov 2. doi:
10.1111/j.1365-2036.2010.04503.x. [Epub ahead of
print]
http://www.ncbi.nlm.nih.gov/pubmed/21083592
Epidemiology,
Diagnostics, and Miscellaneous Works
Humanistic and economic
impacts of hepatitis C infection in the United States. Dibona-ventura
MD, Wagner JS, Yuan Y, L'italien G, Langley P, Ray
Kim W. J Med Econ. 2010 Nov 22. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21091098
Formal patient education improves patient
knowledge of hepatitis c in vulnerable popu-lations. Surjadi M, Torruellas C, Ayala C, Yee HF Jr,
Khalili M. Dig Dis Sci.
2010 Oct 24. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20972850
Visceral
adiposity index is associated with histological findings and high viral load in
patients with chronic hepatitis C due to genotype 1. Petta S, Amato M, Cabibi
D, et al. Hepatology. 2010 Nov;52(5):1543-52.
http://www.ncbi.nlm.nih.gov/pubmed/20799355
Hepatic microRNA
expression is associated with the response to interferon treatment of chronic
hepatitis C. Murakami Y, Tanaka M, Toyoda H, et al. BMC Med Genomics. 2010 Oct 22;3:48.
http://www.ncbi.nlm.nih.gov/pubmed/20969775
Importance
of Patient, Provider, and Facility Predictors of Hepatitis C Virus Treatment in
Veterans: A National Study. Kramer
JR, Kanwal F, Richardson P, et al. Am J Gastroenterol. 2010 Nov 9. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21063393
Syringe
exchange programs --- United States, 2008. Centers for Disease Control and Prevention
(CDC). MMWR Morb Mortal Wkly Rep. 2010 Nov 19;59(45):1488-91.
http://www.ncbi.nlm.nih.gov/pubmed/21085091
Evaluation of acute hepatitis C infection surveillance --- United
States, 2008. MMWR Morb Mortal Wkly Rep. 2010 Nov 5;59(43):1407-10. Centers for Disease
Control and Prevention (CDC).
http://www.ncbi.nlm.nih.gov/pubmed/21048562
Fatigue
and depressive symptoms associated with chronic viral hepatitis patients. health-related quality of life (HRQOL). Karaivazoglou K, Iconomou G, Triantos C, et al. Ann Hepatol.
2010 Oct 1;9(4):419-27.
http://www.ncbi.nlm.nih.gov/pubmed/21057161
Transfusion-transmissible viral infections among US military recipients
of whole blood and platelets during Operation Enduring Freedom and Operation
Iraqi Freedom. Hakre S, Peel SA, O'Connell RJ,
et al. Transfusion. 2010 Oct 7. doi:
10.1111/j.1537-2995.2010.02906.x. [Epub ahead of
print]
http://www.ncbi.nlm.nih.gov/pubmed/20946199
Patients'
perceptions of information and support received from the nurse specialist
during HCV treatment. Grogan A, Timmins F. J Clin Nurs.
2010 Oct;19(19-20):2869-78. doi: 10.1111/j.1365-2702.2010.03239.x.
http://www.ncbi.nlm.nih.gov/pubmed/20846231
Guidance
for clinical trials for children and adolescents with chronic hepatitis C. Wirth S, Kelly D, Sokal
E, et al. J Pediatr Gastroenterol
Nutr. 2010 Nov 10. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21076340
Liver
Cancer
Steatohepatitic hepatocellular
carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C
virus-related cirrhosis with associated NAFLD/NASH. Salomao M, Yu WM, Brown RS Jr,
Emond JC, Lefkowitch JH. Am J Surg Pathol.
2010 Nov;34(11):1630-6.
http://www.ncbi.nlm.nih.gov/pubmed/20975341
Synergistic Effect of Celecoxib on
5-fluorouracil-induced Apoptosis in Hepatocellular
Carcinoma Patients. Bassiouny AR, Zaky
A, Neenaa HM. Ann Hepatol. 2010 Oct 1;9(4):410-8.
http://www.ncbi.nlm.nih.gov/pubmed/21057160
Impact
of viral load of hepatitis C on the incidence of hepatocellular
carcinoma: A population-based cohort study (JPHC Study). Ishiguro S, Inoue M, Tanaka
Y, et al. Cancer Lett.
2010 Oct 28. [Epub ahead of
print]
http://www.ncbi.nlm.nih.gov/pubmed/21035947
Increased
risk for malignant neoplasms among patients with
cirrhosis. Kalaitzakis E, Gunnarsdottir
SA, Josefsson A, Björnsson
E. Clin Gastroenterol Hepatol. 2010 Oct 25. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21029788
Prognostic significance of circumferential cell surface immunoreactivity of glypican-3 in hepatocellular
carcinoma. Yorita K, Takahashi N, Takai H, et al. Liver Int.
2010 Oct 21. doi:
10.1111/j.1478-3231.2010.02359.x. [Epub ahead of
print]
http://www.ncbi.nlm.nih.gov/pubmed/20964802
Factors
associated with use of ultrasonography screening for hepatocellular carcinoma among hepatitis B or C carriers. Cho ER, Shin A, Choi
KS, Lee HY, Kim J. Cancer Epidemiol.
2010 Oct 12. [Epub ahead of
print]
http://www.ncbi.nlm.nih.gov/pubmed/20947465
Resveratrol arrests cell cycle and induces apoptosis in
human hepatocellular Carcinoma Huh-7 cells. Liao PC, Ng LT, Lin LT,
Richardson CD, Wang GH, Lin CC. J Med Food. 2010 Oct 14. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20946021
Comparative
Analysis of outcome in patients with hepatocellular
carcinoma exceeding the Milan criteria treated with liver transplantation
versus partial hepatectomy. Canter RJ, Patel SA, Kennedy T, et al. Am J Clin Oncol. 2010
Oct 8. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20938319
Clinical
Presentation of Hepatocellular Carcinoma (HCC) in
Asian-Americans Versus Non-Asian-Americans. Wong PY, Xia V, Imagawa
DK, Hoefs J, Hu KQ. J Immigr Minor Health. 2010 Oct 2. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20890660
Meta-analysis:
interferon improves outcomes following ablation or resection of hepato-cellular carcinoma. Singal AK, Freeman DH Jr, Anand
BS. Aliment Pharmacol Ther.
2010 Oct;32(7):851-8. doi: 10.1111/j.1365-2036.2010.04414.x.
USA. aksingal@utmb.edu
http://www.ncbi.nlm.nih.gov/pubmed/20659285
Prolonged recurrence-free survival following OK432-stimulated dendritic cell transfer into hepatocellular
carcinoma during transarterial embolization. Nakamoto Y, Mizukoshi E, Kitahara M, et al. Clin Exp Immunol. 2010 Nov 19. doi:
10.1111/j.1365-2249.2010.04246.x. [Epub ahead of
print]
http://www.ncbi.nlm.nih.gov/pubmed/21087443
Effects
of interferon treatment on development and progression of hepatocellular
carcinoma in patients with chronic virus infection: A meta-analysis of
randomized controlled trials. Zhang CH, Xu GL, Jia WD, Li JS, Ma JL, Ge YS. Int J Cancer. 2010 Nov 12. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21077159
Does
antiviral therapy for hepatitis B and C prevent hepatocellular
carcinoma? Lok AS. J Gastroenterol
Hepatol. 2010 Nov 11.
doi: 10.1111/j.1440-1746.2010.06576.x.
[Epub ahead of print]